MedPath

4Kscore Using Serum Stored Uncentrifuged

Completed
Conditions
Prostate Cancer
Registration Number
NCT04130776
Lead Sponsor
OPKO Health, Inc.
Brief Summary

The purpose of the study is to evaluate whether storage of serum uncentrifuged is an allowable preanalytical procedure

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
Male
Target Recruitment
64
Inclusion Criteria
  • Men capable of donating five 5 mL tubes of whole blood
  • 40 to 80 years old
  • No prior diagnosis of prostate cancer; prior negative prostate biopsy included
  • Total PSA (tPSA) value measured within last year to be: at 1.5 ng/mL to 4 ng/mL, 4.1 ng/mL to 10 ng/mL and 10 ng/mL and above
Exclusion Criteria
  • In the previous 96 hours (4 days), underwent a digital rectal exam
  • Any invasive urologic procedure in the 6 months prior to study participation
  • Underwent any procedure to treat symptomatic benign prostatic hyperplasia in the last 6 months
  • Radical prostatectomy since tPSA measurement
  • Received within the previous 6 months 5-alpha reductase inhibitor (5-ARI) therapy such as Avodart (dutasteride) or Proscar (finasteride)

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
fPSA changes in 3 daysDay 0, 1, 2 and 3

Measure fPSA in serum samples at day 0, 1, 2 and 3

hK2 changes in 3 daysDay 0, 1, 2 and 3

Measure hK2 in serum samples at day 0, 1, 2 and 3

tPSA changes in 3 daysDay 0, 1, 2 and 3

Measure tPSA in serum samples at day 0, 1, 2 and 3

iPSA changes in 3 daysDay 0, 1, 2 and 3

Measure iPSA in serum samples at day 0, 1, 2 and 3

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Sidney Kimmel Cancer Center at Thomas Jefferson University

🇺🇸

Philadelphia, Pennsylvania, United States

© Copyright 2025. All Rights Reserved by MedPath